{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T12:42:59Z","timestamp":1783341779625,"version":"3.54.6"},"reference-count":69,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173721"],"award-info":[{"award-number":["82173721"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004763","name":"Natural Science Foundation of Inner Mongolia Autonomous Region","doi-asserted-by":"publisher","award":["2017MS0833"],"award-info":[{"award-number":["2017MS0833"]}],"id":[{"id":"10.13039\/501100004763","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"CAMS Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["2021-I2M-1-029"],"award-info":[{"award-number":["2021-I2M-1-029"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2018YFA0902000"],"award-info":[{"award-number":["2018YFA0902000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003345","name":"Chinese Academy of Meteorological Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003345","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.heliyon.2024.e34392","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T20:07:21Z","timestamp":1720555641000},"page":"e34392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacological validation of a novel exopolysaccharide from Streptomyces sp. 139 to effectively inhibit cytokine storms"],"prefix":"10.1016","volume":"10","author":[{"given":"Zhuochen","family":"Zhuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5179-5005","authenticated-orcid":false,"given":"Liping","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.heliyon.2024.e34392_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.28568","article-title":"Shot-term and long-term rates of postacute sequelea of SARS-CoV-2 infection: a systematic review","volume":"4","author":"Groff","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34392_bib2","doi-asserted-by":"crossref","first-page":"5859","DOI":"10.1038\/s41467-020-19706-9","article-title":"Immune suppression in the early stage of COVID-19 disease","volume":"11","author":"Tian","year":"2020","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e34392_bib3","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced host response to SARS-CoV-2 drives development of COVID-19","volume":"181","author":"Blanco-melo","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2024.e34392_bib4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.cytogfr.2020.12.005","article-title":"The cytokine storm in COVID-19: further advances in our understanding the role of specific chemokines involved","volume":"58","author":"Coperchini","year":"2021","journal-title":"Cytokine Growth Factor Rev."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34392_bib5","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/jmv.26232","article-title":"The cytokine storm and COVID-19","volume":"93","author":"Hu","year":"2021","journal-title":"J. Med. Virol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e34392_bib6","first-page":"203","article-title":"Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia","volume":"43","author":"Chen","year":"2020","journal-title":"Chin. J. Tuberc. Respir. Dis."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e34392_bib7","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.3390\/v13071410","article-title":"Viral load and patterns of SARS-CoV-2 dissemination to the lungs, mediastinal lymph nodes, and spleen of patients with COVID-19 associated lymphopenia","volume":"13","author":"Abdullaev","year":"2021","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34392_bib8","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1038\/s41467-021-22781-1","article-title":"Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection","volume":"12","author":"Diao","year":"2021","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e34392_bib9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with COVID-19","volume":"384","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e34392_bib10","doi-asserted-by":"crossref","unstructured":"C.D. Russel, J.E. Millar, J.K. Baillie. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury, Lancet 395 (10223) 473-475, doi: 10.1016\/S0140-6736(20)30317-2.","DOI":"10.1016\/S0140-6736(20)30317-2"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e34392_bib11","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41440-020-0455-8","article-title":"Interactions of coronaciruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19","volume":"43","author":"Kai","year":"2020","journal-title":"Hypertens. Res."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e34392_bib12","first-page":"906","article-title":"Current status of adverse drugs reactions of cytokine release syndrome","volume":"34","author":"Wang","year":"2018","journal-title":"Chin. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e34392_bib13","first-page":"CD013881","article-title":"Interleukin-6 blocking agents for treating COVID-19: a living systematic review","volume":"6","author":"Ghosn","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.heliyon.2024.e34392_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.804250","article-title":"Specific interleukin-1 inhibitors, specific interleukin-6 inhibitors, and GM-CSF blockades for COVID-19 (at the edge of sepsis): a systematic review","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e34392_bib15","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/cmi2015.36","article-title":"Effect of Ebosin on modulating Interleukin-1b-induced inflammatory responses in rat fibroblast-like synoviocytes","volume":"13","author":"Zhang","year":"2016","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34392_bib16","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1177\/1721727X1301100313","article-title":"Anti-inflammatory effect of Ebosin on rat collagen- induced arthritis through suppression production of interferon-1b, interferon-6 and tumor necrosis factor-a","volume":"11","author":"Zhang","year":"2013","journal-title":"Eur. J. Inflamm."},{"key":"10.1016\/j.heliyon.2024.e34392_bib17","article-title":"Ebosin ameliorates psoriasis-like inflammation of mice via miR-155 targeting tnfaip3 on IL-17 pathway","volume":"12","author":"Guo","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34392_bib18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.toxicon.2017.10.016","article-title":"Exotoxins and endotoxins: inducers of inflammatory cytokines","volume":"149","author":"Cavaillon","year":"2018","journal-title":"Toxicon"},{"key":"10.1016\/j.heliyon.2024.e34392_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.770910","article-title":"Screening of microbial natural products and biological evaluation of Trichomicin as potential anti-cytokine storm agents","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e34392_bib20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.7164\/antibiotics.56.87","article-title":"A new IL-1 receptor inhibitor 139A: fermentation, isolation, physico-chemical properties and structure","volume":"56","author":"Chen","year":"2003","journal-title":"J. Antibiot (Tokyo)"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e34392_bib21","first-page":"1338","article-title":"A mouse model of mycoplasma pneumoniae pneumonia","volume":"33","author":"Liu","year":"2004","journal-title":"Chongqing Medicine"},{"key":"10.1016\/j.heliyon.2024.e34392_bib22","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1165\/ajrcmb.24.5.4315","article-title":"Airway inflammation and bronchial hyperresponsiveness after mycoplasma pneumoniae infction in a murine model","volume":"24","author":"Martin","year":"2001","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34392_bib23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.imbio.2017.10.017","article-title":"Dexmedetomidine mitigate acute lung injury by inhibiting IL-17-induced inflammatory reaction","volume":"223","author":"Zhang","year":"2018","journal-title":"Immunobiology"},{"key":"10.1016\/j.heliyon.2024.e34392_bib24","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1021\/acschemneuro.0c00052","article-title":"Mesenchymal stem cells could be considered as a candidate for further studies in cell-based therapy of alzheimer's disease via targeting the signaling pathways","volume":"11","author":"Farahzadi","year":"2020","journal-title":"ACS Chem. Neurosci."},{"issue":"21","key":"10.1016\/j.heliyon.2024.e34392_bib25","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1056\/NEJM198905253202117","article-title":"Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma","volume":"320","author":"Chatenoud","year":"1989","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e34392_bib26","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/0952-7915(93)90139-J","article-title":"Cytokine dysregulation as a mechanism of graft versus disease","volume":"5","author":"Ferrara","year":"1993","journal-title":"Curr. Opin. Immunol."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e34392_bib27","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/nm1477","article-title":"Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia","volume":"12","author":"de Jong","year":"2006","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e34392_bib28","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/jmv.20255","article-title":"An interferon-\u03b3-related cytokine storm in SARS patients","volume":"75","author":"Huang","year":"2005","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.heliyon.2024.e34392_bib29","author":"Gritti"},{"issue":"Pt B","key":"10.1016\/j.heliyon.2024.e34392_bib30","article-title":"Toll\u2010like receptors in sepsis\u2010associated cytokine storm and their endogenous negative regulators as future immunomodu","volume":"89","author":"Kumar","year":"2020","journal-title":"latory targets"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34392_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-92912-7","article-title":"MYD88, NFKB1, and IL-6 transcripts overexpression are associated with poor outcomes and short survival in neonatal sepsis","volume":"11","author":"AbdAllah","year":"2021","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e34392_bib32","doi-asserted-by":"crossref","first-page":"327","DOI":"10.23812\/CONTI-E","article-title":"Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies","volume":"34","author":"Conti","year":"2020","journal-title":"J. Biol. Regul. Homeost. Agents"},{"issue":"10229","key":"10.1016\/j.heliyon.2024.e34392_bib33","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"issue":"10223","key":"10.1016\/j.heliyon.2024.e34392_bib34","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"issue":"10223","key":"10.1016\/j.heliyon.2024.e34392_bib35","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e34392_bib36","doi-asserted-by":"crossref","first-page":"102763","DOI":"10.1016\/j.ebiom.2020.102763","article-title":"Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients","volume":"55","author":"Liu","year":"2020","journal-title":"EBioMedicine"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e34392_bib37","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.heliyon.2024.e34392_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.615287","article-title":"Prospective: evolution of Chinese medicine to treat COVID-19 patients in China","volume":"11","author":"Wu","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34392_bib39","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12906-017-1585-7","article-title":"The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function","volume":"17","author":"Ding","year":"2017","journal-title":"BMC Compl. Alternative Med."},{"key":"10.1016\/j.heliyon.2024.e34392_bib40","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/637969","article-title":"Effect of lianhuaqingwen capsules on airway inflammation in patients with acute exacerbation of chronic obstructive pulmonary disease","author":"Dong","year":"2014","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.heliyon.2024.e34392_bib41","article-title":"Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)","volume":"156","author":"Li","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.heliyon.2024.e34392_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153242","article-title":"Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial","volume":"85","author":"Hu","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.heliyon.2024.e34392_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.988524","article-title":"A retrospective study of Pupingqinghua prescription versus Lianhuaqingwen in Chinese participants infected with SARS-CoV-2 Omicron variants","volume":"13","author":"Dong","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e34392_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.phyplu.2021.100027","article-title":"Insights into forsythia honeysuckle (Lianhuaqingwen) capsules: a Chinese herbal medicine repurposed for COVID-19 pandemic","volume":"1","author":"Liang","year":"2021","journal-title":"Phytomed Plus."},{"key":"10.1016\/j.heliyon.2024.e34392_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2021.110557","article-title":"Etoricoxib may inhibit cytokine storm to treat COVID-19","volume":"150","author":"Wang","year":"2021","journal-title":"Med. Hypotheses"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e34392_bib46","first-page":"655","article-title":"Selective cox-2 inhibitors: a review of their structure-activity relationships","volume":"10","author":"Zarghi","year":"2011","journal-title":"Iran. J. Pharm. Res. (IJPR)"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e34392_bib47","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/j.1532-2149.2011.00062.x","article-title":"Preoperative administration of etoricoxib in patients undergoing hip replacement causes inhibition of inflammatory mediators and pain relief","volume":"16","author":"Renner","year":"2012","journal-title":"Eur. J. Pain"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e34392_bib48","article-title":"Safety and potential efficacy of cyclooxygenase-2 inhibitors in coronavirus disease 2019, Clin. Transl","volume":"9","author":"Ong","year":"2020","journal-title":"Immunol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e34392_bib49","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3390\/ijms23031049","article-title":"Ibuprofen, Flurbiprofen, Etoricoxib or Paracetamol do not influence ACE2 expression and activity in vitro or in mice and do not exacerbate in-vitro SARS-CoV-2 infection","volume":"23","author":"de Bruin","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e34392_bib50","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S2213-2600(21)00377-5","article-title":"Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial","volume":"9","author":"Declercq","year":"2021","journal-title":"Lancent Respir. Med."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e34392_bib51","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2213-2600(21)00081-3","article-title":"Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial","volume":"9","author":"Soin","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34392_bib52","first-page":"16","article-title":"Into the eye of the cytokine storm","volume":"76","author":"Jennifer","year":"2010","journal-title":"Microbiol. Mol. Biol. Rev."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e34392_bib53","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00281-017-0628-y","article-title":"The meteorology of cytokine storms, and the clinical usefulness of this knowledge","volume":"39","author":"Clark","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.heliyon.2024.e34392_bib54","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.immuni.2013.04.004","article-title":"Tissue-resident macrophages selfmaintain locally throughout adult life minimal contribution from circulating monocytes","volume":"38","author":"Hashimoto","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2024.e34392_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121137","article-title":"M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages","volume":"278","author":"Gunassekaran","year":"2021","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e34392_bib56","first-page":"557","article-title":"Diagnostic value of neutrophil CD11b for neonatal sepsis: a systematic review and meta-analysis","volume":"47","author":"Na","year":"2020","journal-title":"Mod. Prev. Med."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e34392_bib57","first-page":"902","article-title":"Association between expression of nuclear factor-\u03baB, neutrophil CD11b and CD64 in neonates with sepsis and severity of disease","volume":"32","author":"Pang","year":"2022","journal-title":"Chin. J. Nosocomio."},{"issue":"19","key":"10.1016\/j.heliyon.2024.e34392_bib58","first-page":"108","article-title":"Advances in CD11b and CD27 define new subpopulations of human NK cells","volume":"60","author":"Yang","year":"2020","journal-title":"Shandong Med. J."},{"key":"10.1016\/j.heliyon.2024.e34392_bib59","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/pr.2015.66","article-title":"Neutrophil and monocyte toll-like receptor 4, CD11b and reactive oxygen intermediates, and neuroimaging outcomes in preterm infants","volume":"78","author":"O'Hare","year":"2015","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.heliyon.2024.e34392_bib60","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0022-3476(98)70018-6","article-title":"Neutrophil CD11b expression as a diagnostic marker for early-onset neonatal infection","volume":"132","author":"Weirich","year":"1998","journal-title":"J. Pediatr."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e34392_bib61","article-title":"Impaired functions of macrophage from cystic fibrosis patients: CD11b, TLR-5 decrease and sCD14, inflammatory cytokines increase","volume":"8","author":"Jeune","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34392_bib62","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.immuni.2017.12.016","article-title":"The family of LPS signal transducers increases: the arrival of chanzymes","volume":"48","author":"Granucci","year":"2018","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34392_bib63","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12974-019-1538-9","article-title":"Ciprofloxacin and levofloxacin attenuate microglia inflammatory response via TLR4\/NF-\u03baB pathway","volume":"16","author":"Zusso","year":"2019","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.heliyon.2024.e34392_bib64","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/irv.12459","article-title":"Curcumin alleviates macrophage activation and lung inflammation induced by influenza virus infection through inhibiting the NF-\u03baB signaling pathway","volume":"11","author":"Xu","year":"2017","journal-title":"Influenza Other Respir"},{"key":"10.1016\/j.heliyon.2024.e34392_bib65","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/1440-1681.12848","article-title":"Curcumin ameliorates severe influenza pneumonia via attenuating lung injury and regulating macrophage cytokines production","volume":"45","author":"Han","year":"2018","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.heliyon.2024.e34392_bib66","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/archotol.135.2.190","article-title":"Suppression of interleukin 6 and 8 production in head and neck cancer cells with curcumin via inhibition of I\u03ba\u03b2 kinase","volume":"135","author":"Cohen","year":"2009","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.heliyon.2024.e34392_bib67","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.4049\/jimmunol.163.6.3474","article-title":"Curcumin blocks cytokine-mediated NF-\u03baB activation and pro-inflammatory gene expression by inhibiting inhibitory factor I-\u03baB kinase activity","volume":"163","author":"Jobin","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34392_bib68","unstructured":"US National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/home."},{"key":"10.1016\/j.heliyon.2024.e34392_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106749","article-title":"Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19","volume":"86","author":"Zhang","year":"2020","journal-title":"Int. Immunopharm."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024104239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024104239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:45:36Z","timestamp":1778885136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024104239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":69,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2405844024104239"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34392","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological validation of a novel exopolysaccharide from Streptomyces sp. 139 to effectively inhibit cytokine storms","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34392","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e34392"}}